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Adoptive immunotherapy using T cells genetically redir-
ected via expression of chimeric antigen receptors (CARs)
is a promising approach for cancer treatment. However,
this immunotherapy is dependent in part on the optimal
molecular design of the CAR, which involves an extracel-
lular ligand-binding domain connected to an intracellular
signaling domain by spacer and/or transmembrane
sequences. CAR designs frequently incorporate extracellu-
lar linker regions based on the immunoglobulin constant
regions of either IgG1 or IgG4. In this study we evaluated
the potential for the IgG4-Fc linker to result in off-target
interactions between the CAR and Fc gamma receptors
(FcgRs). As proof of principle, we have focused on a
CD19-specific CD19scFv-IgG4-CD28-zeta CAR, and
indeed found that CAR+ T cells bound to soluble FcgRs,
and did not engraft in NSG mice compared to CAR-
negative T cells that only expressed an EGFRt tracking
marker. We hypothesized that mutations to avoid FcgR
interactions would improve CAR+ T cell persistence and
anti-tumor efficacy. To this end, we generated a CD19-
specific CAR that has been mutated at two sites within the
CH2 region (L235E; N297Q) of the IgG4 Fc spacer, here
called CD19R(EQ), as well as a CD19-specific CAR that
has a CH2 deletion in its IgG4 Fc spacer (CD19Rch2Δ).
These mutations/deletion do not alter the functional
ability of the CAR, when expressed by T cells, to mediate
antigen-specific lysis of tumor cells. However, compared
to T cells that express a non-mutated CAR, T cells expres-
sing the CD19R(EQ) and CD19Rch2Δ exhibit impaired
binding to recombinant soluble FcgRs. These CD19R(EQ)
and CD19Rch2Δ T cells also exhibit improved engraft-
ment in NSG mice. Indeed the engraftment levels seen
with the mutated CAR were similar to that seen with
CAR-negative T cells that only expressed the EGFRt track-
ing marker. Importantly, elimination of CAR/FcgR interac-
tions also significantly improves CD19-specific CAR+ T
cell anti-lymphoma efficacy in NSG mice. These studies
provide evidence that optimal CAR function necessitates
the elimination of cellular FcgR interactions in order to
improve T cell persistence and anti-tumor responses.
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